News
MSD joins PD-1/VEGF push in cancer with LaNova deal
There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy.
News
Syncona aims Slingshot at biotech's 'translational gap'
UK-based life science investor Syncona has launched a new company – Slingshot Therapeutics – with a mission to find promising projects in academia and translate them into full-blown develop
News
GSK hails survival data with revived myeloma drug Blenrep
GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached stat
News
Metsera gets $215m for obesity trials, and other financings
If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York start-up Metsera.
R&D
Partner Content
Returning... The 5th Operationalize Expanded Access Programs...
Welcome to, or welcome back to, the 5th Operationalize: Expanded Access Programs Summit 2025!
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
